N/A
N=13
Dark Chocolate and Glucose Levels in Diabetes
Type 2 Diabetes · Type 1 Diabetes
Bottom Line
View on ClinicalTrials.gov: NCT04847999 ↗Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Feb 2025
Primary outcome: Primary: Blood Glucose Incremental Area Under the Curve — 240.5; 83.81 mM x 120 minutes
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Dark chocolate (Dietary_supplement)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of British Columbia
- Primary completion
- May 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Blood Glucose Incremental Area Under the Curve |
240.5; 83.81 | — |
| SECONDARY Peak Blood Glucose Concentration |
10.6; 11.9 | — |
| SECONDARY Peak Blood Glucose Concentration Above Baseline |
2.2; 3.5 | — |
| SECONDARY Blood Glucose |
1090.8; 1247.5 | — |
Summary
Diabetes is a growing concern in the world with an estimated 9.3% of adults, ages 20-79, with it in 2019, type 2 diabetes accounting for 90% of this total. A common recommendation for individuals with diabetes is to limit sugars and sweets as it may cause a high blood glucose response. As a result, chocolate is often avoided due to the sugar content; though, high-polyphenol chocolate may have a beneficial effect on hyperglycaemia and vascular function. The sugar-free chocolate from Ross Chocolates is formulated with a blend of inulin, erythritol, and stevia. These alternatives to sugar are not expected to cause a significant change in blood glucose levels following consumption. The main objective of this study is to verify glucose levels before and after consumption of Ross Chocolates' blend of sweeteners dark chocolate and conventional chocolate in people with diabetes.
Eligibility Criteria
Inclusion Criteria
- physician-diagnosed T1D or T2D of ≥1 year;
- current HbA1c of 6.5-8.5%;
- BMI: 25-40 kg/m2;
- blood pressure of <160/99 mm Hg assessed according to guidelines;
- non-smoking;
- not on hormone replacement therapy, corticosteroids, or anti-inflammatory medications;
- 18-75 years old.
Exclusion Criteria
- Are taking more than 2 glucose lowering medications;
- Are ongoing medical treatment for diseases such as cancer, auto-immune or inflammatory disease, liver or kidney disorders;
- Have allergy, intolerance or aversion to cocoa, stevia, erythritol, inulin, or any other dietary restrictions (e.g., vegan) that will prevent them from following the standardized study diets;
- Are unable to follow remote guidance by internet or smartphone;
- Are unable to follow the controlled diet instructions;
- Are unable to read or communicate in English.
Data sourced from ClinicalTrials.gov (NCT04847999). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.